Greenwich LifeSciences (GLSI) Retained Earnings (2019 - 2025)
Greenwich LifeSciences (GLSI) posted Retained Earnings of -$87.1 million for Q4 2025, down 12.31% on a QoQ basis from -$77.6 million in Q3 2025, and down 28.56% year-over-year from -$122.0 million in Q4 2024.
Greenwich LifeSciences (GLSI) Retained Earnings (2019 - 2025) Analysis & Trends
Greenwich LifeSciences' Retained Earnings history runs 7 years deep, the most recent figure standing at -$87.1 million for Q4 2025.
- Quarterly Retained Earnings fell 28.56% year-over-year to -$87.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$87.1 million (down 28.56% YoY) and the FY2025 annual result came in at -$87.1 million, down 28.56% from the prior year.
- Retained Earnings was -$87.1 million for Q4 2025 at Greenwich LifeSciences, down from -$77.6 million in the prior quarter.
- Across five years, Retained Earnings topped out at $59.6 million in Q2 2021 and bottomed at -$87.1 million in Q4 2025.
- A 5-year average of -$45.8 million and a median of -$46.4 million in 2023 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2021 — Retained Earnings declined 12.04% — and 2022, when it plunged 161.04%.
- Greenwich LifeSciences' Retained Earnings stood at -$33.6 million in 2021, then declined by 23.26% to -$41.5 million in 2022, then declined by 21.44% to -$50.4 million in 2023, then slumped by 34.58% to -$67.8 million in 2024, then declined by 28.56% to -$87.1 million in 2025.
- Business Quant data shows GLSI's Retained Earnings at -$87.1 million in Q4 2025, -$77.6 million in Q3 2025, and -$73.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Greenwich LifeSciences | 178.53 Mn | 178.53 Mn | - | -87.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -87.14 Mn |
| Sep 30, 2025 | -77.59 Mn |
| Jun 30, 2025 | -73.44 Mn |
| Mar 31, 2025 | -69.41 Mn |
| Dec 31, 2024 | -67.78 Mn |
| Sep 30, 2024 | -58.11 Mn |
| Jun 30, 2024 | -55.44 Mn |
| Mar 31, 2024 | -52.84 Mn |
| Dec 31, 2023 | -50.36 Mn |
| Sep 30, 2023 | -47.62 Mn |
| Jun 30, 2023 | -45.23 Mn |
| Mar 31, 2023 | -43.60 Mn |
| Dec 31, 2022 | -41.47 Mn |
| Sep 30, 2022 | -38.68 Mn |
| Jun 30, 2022 | -36.36 Mn |
| Mar 31, 2022 | -35.62 Mn |
| Dec 31, 2021 | -33.65 Mn |
| Sep 30, 2021 | -31.29 Mn |
| Jun 30, 2021 | 59.57 Mn |
| Mar 31, 2021 | -29.67 Mn |